Skip to main content

Advertisement

SpringerLink
Log in

Efficacy of Concomitant Elemental Diet Therapy in Scheduled Infliximab Therapy in Patients with Crohn’s Disease to Prevent Loss of Response

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Loss of response (LOR) to infliximab (IFX) has become an important clinical issue for patients with Crohn’s disease (CD). Elemental diet (ED) therapy has been established as a nutrition therapy for CD in Japan. ED therapy can reduce antigen exposure and is both efficacious and safe.

Aim

To evaluate the efficacy of concomitant ED therapy in maintaining regular IFX infusion in patients with CD.

Methods

We retrospectively studied 125 patients with luminal CD treated with scheduled IFX maintenance therapy with a regular dosage. Patients were classified into two groups: the ED group with intake ≥900 kcal/day and the non-ED group with intake <900 kcal/day. When clinical LOR was detected on the basis of disease activity, laboratory parameters, or endoscopic findings, the physician discontinued the infusion schedule of IFX. We investigated the efficacy of ED therapy for sustaining the scheduled IFX maintenance therapy.

Results

With the exception of ED intake, no significant differences were found in patient characteristics between the ED group and the non-ED group. The ED group was significantly superior to the non-ED group (p = 0.049) in sustaining scheduled IFX maintenance therapy. It is well known that ED therapy is more effective for small bowel lesions than colonic lesions in CD. When comparing ileitis and ileocolitis patients with CD, the ED group was significantly superior to the non-ED group (p = 0.015).

Conclusions

Concomitant ED therapy is effective in maintaining scheduled IFX maintenance therapy in patients with luminal CD in order to prevent LOR.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. N Engl J Med. 1997;337:1029–1035.

    Article  CAS  PubMed  Google Scholar 

  2. Hanauer SB, Fegan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s diseasee: the ACCENT I randomized trial. Lancet. 2002;359:1541–1549.

    Article  CAS  PubMed  Google Scholar 

  3. Bhatia JK, Korelitz BI, Panagopoulos G, et al. A prospective open-label trial of Remicade in patients with severe exacerbation of Crohn’s disease requiring hospitalization: a comparison with outcomes previously observed in patients receiving intravenous hydrocortisone. J Clin Gastroenterol. 2007;41:677–681.

    Article  CAS  PubMed  Google Scholar 

  4. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in CD. Inflamm Bowel Dis. 2009;15:1295–1301.

    Article  PubMed  Google Scholar 

  5. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.

    Article  CAS  PubMed  Google Scholar 

  6. Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010;15:1383–1395.

    Article  Google Scholar 

  7. Mackey AC, Green L, Leptak C. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease: update. J Pediatr Gastroenterol Nutr. 2009;48:386–388.

    Article  PubMed  Google Scholar 

  8. Takagi S, Utsunomiya K, Kuriyama S, et al. Effectiveness of an ‘half elemental diet’ as maintenance therapy for Crohn’s disease: a randomized-controlled trial. Aliment Pharmacol Ther. 2006;24:1333–1400.

    Article  CAS  PubMed  Google Scholar 

  9. Tanaka T, Takahama K, Kimura T, et al. Effect of concurrent elemental diet on infliximab treatment for Crohn’s disease. J Gastroenterol Hepatol. 2006;21:1143–1149.

    Article  CAS  PubMed  Google Scholar 

  10. Hirai F, Ishihara H, Yada S, et al. Effectiveness of concomitant enteral nutrition therapy and infliximab for maintenance treatment of Crohn’s disease in adults. Dig Dis Sci. 2013;58:1329–1334.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  11. Satsangi J, Silverberg MS, Vermeire S. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749–753.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  12. Matsueda K, Shoda R, Takazoe M, et al. Therapeutic efficacy of cyclic home elemental enteral alimentation in Crohn’s disease: Japanese Cooperative Crohn’s Disease Study. J Gastroenterol. 1995;30:91–94.

    PubMed  Google Scholar 

  13. Hirakawa H, Fukuda Y, Tanida N, et al. Home elemental enteral hyperalimentation (HEEH) for maintenance of remission in patients with Crohn’s disease. Gastroenterol Jpn. 1993;28:379–384.

    CAS  PubMed  Google Scholar 

  14. Wilschanski M, Sherman P, Pencharz P, et al. Supplementary enteral nutrition maintains remission in paediatric Crohn’s disease. Gut. 1996;38:543–548.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  15. Gisbert JP, Panes J. Loss of response and requirement of infliximab dose intensification in Crohn’s disease: a review. Am J Gastroenterol. 2009;104:760–767.

    Article  CAS  PubMed  Google Scholar 

  16. Maser EA, Villela R, Silverberg MS, et al. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn’s disease. Clin Gastroenterol Hepatol.. 2006;4:1248–1254.

    Article  CAS  PubMed  Google Scholar 

  17. Nanda KS, Cheifetz AS, Moss AC. Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis. Am J Gastroenterol. 2013;108:40–47.

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  18. Vande Casteele N, Gils A, Singh S, et al. Antibody response to infliximab and its impact on pharmacokinetics can be transient. Am J Gastroenterol. 2013;108:962–971.

    Article  PubMed  Google Scholar 

  19. D’Haens GR, Panaccione R, Higgins PD, et al. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn’s and colitis organization: when to start, when to stop, which drug to choose, and hot to predict response? Am J Gastroenterol. 2011;106:199–212.

    Article  PubMed  Google Scholar 

  20. Verma S, Kirkwood B, Brown S, et al. Oral nutritional supplementation is effective in the maintenance of remission in Crohn’s disease. Dig Liver Dis. 2000;32:769–774.

    Article  CAS  PubMed  Google Scholar 

  21. Lochs H. Enteral nutrition—the new maintenance therapy in Crohn’s disease? Inflamm Bowel Dis. 2007;13:1581–1582.

    Article  PubMed  Google Scholar 

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka, 545-8585, Japan

    Noriko Kamata, Kimihiko Watanabe, Shuhei Hosomi, Atsushi Noguchi, Tomomi Yukawa, Hirokazu Yamagami, Matsatsugu Shiba, Tetsuya Tanigawa, Toshio Watanabe, Kazunari Tominaga, Yasuhiro Fujiwara & Tetsuo Arakawa

  2. Department of Medicine, Social Welfare Service Corporation, Ishii Memorial Aizen-en, Aizeznbashi Hospital, 5-16-15, Nihonbashi, Naniwa-ku, Osaka, 595-0029, Japan

    Nobuhide Oshitani

  3. Department of Gastroenterology, Osaka City General Hospital, 2-13-22, Miyakojima Hondouri, Miyakojima-ku, Osaka, 534-0021, Japan

    Kenji Watanabe

Authors
  1. Noriko Kamata
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nobuhide Oshitani
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kenji Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kimihiko Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shuhei Hosomi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Atsushi Noguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomomi Yukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hirokazu Yamagami
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Matsatsugu Shiba
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Tetsuya Tanigawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Toshio Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Kazunari Tominaga
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Yasuhiro Fujiwara
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Tetsuo Arakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Noriko Kamata.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kamata, N., Oshitani, N., Watanabe, K. et al. Efficacy of Concomitant Elemental Diet Therapy in Scheduled Infliximab Therapy in Patients with Crohn’s Disease to Prevent Loss of Response. Dig Dis Sci 60, 1382–1388 (2015). https://doi.org/10.1007/s10620-014-3493-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-014-3493-8

Keywords

Search

Navigation